pp-271 Solution for injection/infusion
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Insulin dependent diabetes
Clinical stage: Phase 2
Modality: Peptide
Mechanism & Target: Not disclosed
Route & form: SC injection / IV infusion
Differentiation: The coformulation of pramlintide, an amylin analog, at a fixed ratio with mealtime insulin, mimicks normal physiology and may deliver improved glycemic control (more time in target range) with reductions in insulin requirements and weight.
Manufacturer #39682
A late-stage clinical biopharmaceutical company focused on metabolic diseases. Developing a biologic therapeutic targeting metabolic diseases with global development focus. Pipeline positioned for regulatory advancement in key markets.
None